Trial Profile
An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 12 May 2016 New trial record